Is Autolus Therapeutics plc (AUTL) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 13.1% / 30% | 146.3% / 30% | 12.0% / 30% | 319.71% / 5% | ✗ NOT HALAL |
| DJIM | 13.1% / 33% | 146.3% / 33% | 12.0% / 33% | 319.71% / 5% | ✗ NOT HALAL |
| MSCI | 6.7% / 33% | 75.1% / 33% | 6.2% / 33% | 319.71% / 5% | ✗ NOT HALAL |
| S&P | 13.1% / 33% | 146.3% / 33% | 12.0% / 33% | 319.71% / 5% | ✗ NOT HALAL |
| FTSE | 6.7% / 33% | 75.1% / 33% | 6.2% / 50% | 319.71% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -264.8% | |
| Operating Margin | -337.9% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -60.6% | |
| Return on Assets (ROA) | -23.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$206M |
| Free Cash Flow | -$241M |
| Total Debt | $53M |
| Debt-to-Equity | 122.5 |
| Current Ratio | 6.2 |
| Total Assets | $783M |
Price & Trading
| Last Close | $1.29 |
| 50-Day MA | $1.49 |
| 200-Day MA | $1.71 |
| Avg Volume | 1.9M |
| Beta | 2.0 |
|
52-Week Range
$1.10
| |
About Autolus Therapeutics plc (AUTL)
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Autolus Therapeutics plc (AUTL) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Autolus Therapeutics plc is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Autolus Therapeutics plc's debt ratio?
Autolus Therapeutics plc's debt ratio is 13.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 6.7%.
What are Autolus Therapeutics plc's key financial metrics?
Autolus Therapeutics plc has a market capitalization of $322M, and revenue of $10M. Return on equity stands at -60.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.